1) Pharmacy of the worldIn December 2022, Intas received a list of observations from the US Food and Drug Administration (FDA) regarding data integrity and quality compliance. A few weeks ago, Sun Pharma hit a pause on releasing US-bound drugs after getting a non-compliance letter from US FDA. India has seen the highest number of US FDA inspections—64 in 2022 and 55 in 2023 (so far). Are these compliance moves threatening India's title of 'pharmacy of the world'? Keeping pace with the regulations while maintaining growth in the generics drugs manufacturing industry has been challenging for Indian pharma companies. Though generics manufacturing is expensive and less profitable, the volumes are allowing pharma giants to make a large chunk of their revenue from this sector for now. But can this jugaad sustain the growth and churn out profit for generic drug makers? Read more